TMSB10 and central nervous system cancer: Collectively, these results highlighted that TMSB10 may serve as a potential prognostic biomarker and immunotherapy target in glioma, as its knockdown significantly improved the efficacy of selumetinib and anti-PD1 treatment, providing a promising strategy for improving the response to targeted combination therapy for glioma patients.